Resapp Health Share Price and Company Fundamentals
Last traded: Last Friday at 5:58 AM
ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a smartphone application that allows consumers to self-assess the risk of sleep apnoea. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was incorporated in 2000 and is headquartered in Brisbane, Australia.
|Primary activities||Research and development of digital healthcare solutions for respiratory disease|
|Industry / Sector||Health Information Services / Healthcare|
|Mailing address||100 Creek Street Level 12 Brisbane QLD 4000 Australia|
|Phone / Fax||61 7 3724 0035 / 61 8 9218 8875|
|Share registry||LINK MARKET SERVICES LIMITED|
Resapp Health does not pay dividends.
As of Sep 2021, following are the company executives and directors listed on Resapp Health.
|Dr. Anthony Keating||CEO, MD & Director||293.45k|
|Mr. Brian Leedman B.Econ., BECON, M.B.A.||Exec. Director of Corp. Affairs & Exec. Director||18.47k|
|Al Rey Lunar CPA||VP of Fin.|
|Ms. Nicki Farley||Company Sec.||44|
|Dr. Clas KÃ¤llander||Founder and Director of R&D of Cavidi AB|
|Dr. Paul Porter||Scientific Advisor|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Resapp Health is 69.59M and its enterprise value is 58.9M. The enterprise value to revenue ratio of RAP is 844.71.
The RAP's stocks Beta value is 0.63 making it 37% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Resapp Health (RAP)
- Ansell (ANN)
- Cochlear (COH)
- Estia Health (EHE)
- Fisher & Paykel Healthcare Corporation (FPH)
- Healius (HLS)
- Nanosonics (NAN)
- Polynovo (PNV)
- Pro Medicus (PME)
- Ramsay Health Care (RHC)
- Resmed Inc (RMD)
- Sonic Healthcare (SHL)
Resapp Health (ASX:RAP) Frequently Asked Questions
1. What is Resapp Health's Stock Symbol?
Resapp Health trades on ASX under the ticker symbol "RAP".
2. What is Resapp Health's stock price today?
One share of RAP stock can currently be purchased for approximately $0.081.
3. How can I contact Resapp Health?
Resapp Health's mailing address is 100 Creek Street Level 12 Brisbane QLD 4000 Australia. The company can be reached via phone at 61 7 3724 0035.
4. What is Resapp Health's official website?
The official website of Resapp Health is http://www.resapphealth.com.au.
5. Which share registry manages Resapp Health's stock?
Resapp Health's stock is managed by LINK MARKET SERVICES LIMITED.